(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 9.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.27%.
Veracyte's revenue in 2026 is $561,900,000.On average, 14 Wall Street analysts forecast VCYT's revenue for 2026 to be $48,087,323,562, with the lowest VCYT revenue forecast at $45,505,173,283, and the highest VCYT revenue forecast at $50,047,249,584. On average, 14 Wall Street analysts forecast VCYT's revenue for 2027 to be $53,795,869,371, with the lowest VCYT revenue forecast at $50,057,700,379, and the highest VCYT revenue forecast at $57,458,471,075.
In 2028, VCYT is forecast to generate $59,131,402,187 in revenue, with the lowest revenue forecast at $53,710,655,196 and the highest revenue forecast at $62,658,143,556.